Data with investigational Taxotere(R) regimens in the management of breast
cancer, across several disease stages, to be presented
BRIDGEWATER, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Among the 62 oral
abstracts accepted for presentation at the 30th annual San Antonio Breast
Cancer Symposium (SABCS), six with Taxotere(R) (docetaxel) Injection
Concentrate investigational regimens will be presented in plenary sessions.
-- Plenary Lecture 1 on the opening day of the symposium will review data
for systemic adjuvant therapies being investigated for the treatment
of breast cancer.
"The worldwide overview: New results for systemic adjuvant therapies."
Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG),
University of Oxford, UK.
Thursday, December 13, 2007, 8:55 AM / Plenary lecture 1, Exhibit Hall D
-- The data from studies with Taxotere(R)-based regimens and
anthracycline-based regimens will be discussed through two
Abst 12: "Extended follow-up and analysis by age of the US Oncology
Adjuvant trial 9735." Jones S, et al; US Oncology Research, Inc., Houston,
Thursday, December 13, 2007, 9:45AM / Plenary lecture 1, Exhibit Hall D
This presentation includes the updated analysis (seven years median
follow-up) of a randomized trial comparing four cycles of a standard
anthracycline regimen, doxorubicin/cyclophosphamide (AC), to a non
anthracycline regimen, Taxotere(R)/cyclophosphamide (TC). New
findings regarding overall survival as well as the effect of age on
efficacy and safety will be presented.
Abst 13: "Role of anthracycline-based therapy in the adjuvant treatment
of breast cancer: efficacy analyses determined by molecular subtypes of the
disease." Slamon DJ, et al; Cancer International Research Group (CIRG),
Edmonton, AB, Canada.
Copyright©2007 PR Newswire.
All rights reserved